{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:22:22Z","timestamp":1791343342499,"version":"4.3.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,7]],"date-time":"2015-04-07T00:00:00Z","timestamp":1428364800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.antiviral.2015.01.004","type":"journal-article","created":{"date-parts":[[2015,1,20]],"date-time":"2015-01-20T02:18:00Z","timestamp":1421720280000},"page":"89-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"special_numbering":"C","title":["A path to eradication of hepatitis C in low- and middle-income countries"],"prefix":"10.1016","volume":"119","author":[{"given":"Camilla S.","family":"Graham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Swan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.antiviral.2015.01.004_b0005","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/jmv.21788","article-title":"Genotypes and viral load of hepatitis C virus among persons attending a voluntary counseling and testing center in Ethiopia","volume":"83","author":"Abreha","year":"2011","journal-title":"J. Med. Virol."},{"issue":"2","key":"10.1016\/j.antiviral.2015.01.004_b0010","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/QAI.0b013e31827ce536","article-title":"Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria","volume":"62","author":"Agbaji","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"10","key":"10.1016\/j.antiviral.2015.01.004_b0015","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002","volume":"144","author":"Armstrong","year":"2006","journal-title":"Ann. Intern. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2015.01.004_b0020","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1093\/cid\/cis361","article-title":"Global burden of hepatitis C: considerations for healthcare providers in the United States","volume":"55","author":"Averhoff","year":"2012","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.antiviral.2015.01.004_b0025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1423-0410.2012.01640.x","article-title":"Reduction of the risk of transfusion-transmitted viral infection by nucleic acid amplification testing in the Western Cape of South Africa: a 5-year review","volume":"104","author":"Cable","year":"2013","journal-title":"Vox Sang."},{"issue":"4","key":"10.1016\/j.antiviral.2015.01.004_b0030","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/jmv.21724","article-title":"Analysis of hepatitis C virus strains circulating in Republic of the Congo","volume":"82","author":"Cantaloube","year":"2010","journal-title":"J. Med. Virol."},{"issue":"18","key":"10.1016\/j.antiviral.2015.01.004_b0035","first-page":"357","article-title":"Vital signs: evaluation of hepatitis C virus infection testing and reporting \u2013 eight U.S. sites, 2005\u20132011","volume":"62","year":"2013","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"11","key":"10.1016\/j.antiviral.2015.01.004_b0040","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-158-11-201306040-00005","article-title":"Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review","volume":"158","author":"Chou","year":"2013","journal-title":"Ann. Intern. Med."},{"issue":"Suppl. 2","key":"10.1016\/j.antiviral.2015.01.004_b0045","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1093\/cid\/cit329","article-title":"Hepatitis C virus vaccines among people who inject drugs","volume":"57","author":"Cox","year":"2013","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.antiviral.2015.01.004_b0050","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","article-title":"Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.antiviral.2015.01.004_b0055","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2893.2009.01196.x","article-title":"The impact of the prevention programme of hepatitis C over more than a decade: the French experience","volume":"17","author":"Delarocque-Astagneau","year":"2010","journal-title":"J. Viral Hepat."},{"issue":"23","key":"10.1016\/j.antiviral.2015.01.004_b0060","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa0707615","article-title":"Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon","volume":"359","author":"Di Bisceglie","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.01.004_b0065","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fmicb.2014.00329","article-title":"Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies","volume":"5","author":"Drummer","year":"2014","journal-title":"Front Microbiol."},{"issue":"7350","key":"10.1016\/j.antiviral.2015.01.004_b0070","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/474S18a","article-title":"Perspective: test and treat this silent killer","volume":"474","author":"Edlin","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2015.01.004_b0075","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.antiviral.2014.07.015","article-title":"Can hepatitis C be eradicated in the United States?","volume":"110","author":"Edlin","year":"2014","journal-title":"Antiviral Res."},{"issue":"Pt 7","key":"10.1016\/j.antiviral.2015.01.004_b0080","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1099\/vir.0.042184-0","article-title":"Epidemic history of hepatitis C virus infection in two remote communities in Nigeria, West Africa","volume":"93","author":"Forbi","year":"2012","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2015.01.004_b0085","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.antiviral.2014.01.002","article-title":"Can hepatitis C virus infection be eradicated in people who inject drugs?","volume":"104","author":"Grebely","year":"2014","journal-title":"Antiviral Res."},{"issue":"1","key":"10.1016\/j.antiviral.2015.01.004_b0090","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1258\/095646204322637182","article-title":"The global burden of disease attributable to contaminated injections given in health care settings","volume":"15","author":"Hauri","year":"2004","journal-title":"Int. J. STD AIDS"},{"issue":"7","key":"10.1016\/j.antiviral.2015.01.004_b0095","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/cid\/ciu012","article-title":"Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries","volume":"58","author":"Hill","year":"2014","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.antiviral.2015.01.004_b0100","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/cid\/cit245","article-title":"Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort","volume":"57","author":"Holmberg","year":"2013","journal-title":"Clin. Infect. Dis."},{"issue":"20","key":"10.1016\/j.antiviral.2015.01.004_b0105","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1056\/NEJMp1302973","article-title":"Hepatitis C in the United States","volume":"368","author":"Holmberg","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.01.004_b0110","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.meegid.2013.01.021","article-title":"Hepatitis C virus infections in the Democratic Republic of Congo exhibit a cohort effect","volume":"19","author":"Iles","year":"2013","journal-title":"Infect. Genet. Evol."},{"issue":"20","key":"10.1016\/j.antiviral.2015.01.004_b0115","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1056\/NEJMp1400160","article-title":"Treating hepatitis C in lower-income countries","volume":"370","author":"Jayasekera","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.antiviral.2015.01.004_b0120","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/hep.26387","article-title":"Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis","volume":"58","author":"Larney","year":"2013","journal-title":"Hepatology"},{"issue":"9323","key":"10.1016\/j.antiviral.2015.01.004_b0125","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(02)08911-0","article-title":"Differential pricing of drugs: a role for cost-effectiveness analysis?","volume":"359","author":"Lopert","year":"2002","journal-title":"Lancet"},{"issue":"9859","key":"10.1016\/j.antiviral.2015.01.004_b0130","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"issue":"9635","key":"10.1016\/j.antiviral.2015.01.004_b0135","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(08)61116-2","article-title":"Acute hepatitis C","volume":"372","author":"Maheshwari","year":"2008","journal-title":"Lancet"},{"issue":"Suppl. 2","key":"10.1016\/j.antiviral.2015.01.004_b0140","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1093\/cid\/cit296","article-title":"Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy","volume":"57","author":"Martin","year":"2013","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.antiviral.2015.01.004_b0145","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/hep.26431","article-title":"Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals","volume":"58","author":"Martin","year":"2013","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.antiviral.2015.01.004_b0150","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.23561","article-title":"Institute of medicine recommendations for the prevention and control of hepatitis B and C","volume":"51","author":"Mitchell","year":"2010","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.antiviral.2015.01.004_b0155","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.01.004_b0160","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1744-8603-7-39","article-title":"A win-win solution? A critical analysis of tiered pricing to improve access to medicines in developing countries","volume":"7","author":"Moon","year":"2011","journal-title":"Global Health"},{"issue":"12","key":"10.1016\/j.antiviral.2015.01.004_b0165","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/cid\/cit602","article-title":"High frequency of false-positive hepatitis C virus enzyme-linked immunosorbent assay in Rakai, Uganda","volume":"57","author":"Mullis","year":"2013","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.antiviral.2015.01.004_b0170","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1086\/422606","article-title":"Viral gene sequences reveal the variable history of hepatitis C virus infection among countries","volume":"190","author":"Nakano","year":"2004","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.antiviral.2015.01.004_b0175","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4103\/0970-0218.96093","article-title":"Estimating the burden of disease from unsafe injections in India: a cost-benefit assessment of the auto-disable syringe in a country with low blood-borne virus prevalence","volume":"37","author":"Reid","year":"2012","journal-title":"Indian J. Community Med."},{"issue":"4","key":"10.1016\/j.antiviral.2015.01.004_b0180","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-156-4-201202210-00378","article-title":"The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings","volume":"156","author":"Rein","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2015.01.004_b0185","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/1741-7015-11-234","article-title":"Managing HIV\/hepatitis C co-infection in the era of direct acting antivirals","volume":"11","author":"Rockstroh","year":"2013","journal-title":"BMC Med."},{"issue":"8","key":"10.1016\/j.antiviral.2015.01.004_b0190","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/jmv.21817","article-title":"Poor performance of hepatitis C antibody tests in hospital patients in Uganda","volume":"82","author":"Seremba","year":"2010","journal-title":"J. Med. Virol."},{"issue":"1","key":"10.1016\/j.antiviral.2015.01.004_b0195","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.mayocp.2011.08.001","article-title":"Viral hepatitis among Somali immigrants in Minnesota: association of hepatitis C with hepatocellular carcinoma","volume":"87","author":"Shire","year":"2012","journal-title":"Mayo Clin. Proc."},{"issue":"RR-4","key":"10.1016\/j.antiviral.2015.01.004_b0200","first-page":"1","article-title":"Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945\u20131965","volume":"61","author":"Smith","year":"2012","journal-title":"MMWR Recomm. Rep."},{"issue":"24","key":"10.1016\/j.antiviral.2015.01.004_b0205","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.antiviral.2015.01.004_b0210","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1128\/AAC.02788-14","article-title":"Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity","volume":"58","author":"Wang","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.antiviral.2015.01.004_b0215","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2471\/BLT.12.102780","article-title":"Low-cost tools for diagnosing and monitoring HIV infection in low-resource settings","volume":"90","author":"Wu","year":"2012","journal-title":"Bull. World Health Organ."},{"issue":"11","key":"10.1016\/j.antiviral.2015.01.004_b0220","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/j.1365-3156.2011.02845.x","article-title":"HCV prevalence and co-infection with HIV among pregnant women in Saint Camille Medical Centre, Ouagadougou","volume":"16","author":"Zeba","year":"2011","journal-title":"Trop. Med. Int. Health"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215000054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215000054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T02:27:26Z","timestamp":1537928846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354215000054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":44,"alternative-id":["S0166354215000054"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.01.004","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A path to eradication of hepatitis C in low- and middle-income countries","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}